NASDAQ$OKUR
OnKure Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the quarter ended September 30, 2022.
Reneo Pharmaceuticals reported a net loss of $13.0 million, or $0.53 per share, for the three months ended September 30, 2022. The company had approximately $116 million in cash, cash equivalents and short-term investments as of September 30, 2022. They have achieved over 80% enrollment in the ongoing pivotal STRIDE study in primary mitochondrial myopathy (PMM) patients with mitochondrial DNA (mtDNA) defects and remain on track to announce topline data from this study in the fourth quarter of 2023.
- Enrolled over 80% of the population in the ongoing pivotal STRIDE study
- Positive data from the STRIDE and STRIDE AHEAD studies could potentially support registration of REN001 for PMM patients with mtDNA defects
- Announced plans to study REN001 in PMM patients with nDNA defects
- Announced successful Phase 1b study in LC-FAOD patients with nDNA defects, and plans to move the program forward into Phase 2 development
Headline financials
Revenue & EPS history
Reneo Pharmaceuticals · Revenue · Quarterly
$458K
Forward guidance
Completion of enrollment in the pivotal STRIDE study in the first quarter of 2023; topline data in the fourth quarter of 2023. Meetings with regulatory agencies to discuss a Phase 2 study for LC-FAOD patients in the fourth quarter of 2022; update to be provided in the first quarter of 2023. Update on plans to study REN001 in PMM patients with nDNA defects in the first quarter of 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+2.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.6%
Avg return
30 days after
52%
11 / 21 earnings
Positive
+21.2%
Q2 2025
Best reaction
-10.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | -15.0% | -6.3% | |
| Q3 2025 | -5.5% | -2.5% | -3.2% | |
| Q2 2025 | +21.2% | +24.6% | +20.2% | |
| Q1 2025 | +12.5% | +7.5% | +21.0% | |
| Q4 2024 | +3.7% | +4.8% | -40.0% | |
| Q3 2024 | +3.2% | +1.8% | -16.7% | |
| Q2 2024 | +9.7% | +15.7% | +5.2% | |
| Q1 2024 | +2.4% | +3.0% | +0.6% | |
| Q4 2023 | +3.0% | +3.6% | +1.2% | |
| Q3 2023 | -0.9% | +5.6% | +21.1% | |
| Q2 2023 | -6.3% | -15.1% | +7.1% | |
| Q1 2023 | -1.4% | -0.9% | +79.3% | |
| Q4 2022 | -10.3% | -1.0% | +65.1% | |
| Q3 2022 | -3.0% | -8.6% | -35.4% | |
| Q2 2022 | -3.0% | +4.1% | +34.6% | |
| Q1 2022 | -5.9% | -10.8% | -28.2% | |
| Q4 2021 | -1.4% | -6.8% | -34.7% | |
| Q3 2021 | +14.8% | +5.7% | -13.2% | |
| Q2 2021 | +0.1% | -3.2% | +2.0% | |
| Q4 2020 | +7.5% | +2.9% | -2.3% | |
| Q1 2021 | +7.5% | +2.9% | -2.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro